dr. volkow, thank you for coming to new hampshire. i especially appreciate the work that's being done to address the opioid epidemic, like my league clos on this -- colleagues on many committee, we have been very hard hit in new hampshire, as you know, from your visit to catholic medical center and other places in the state. i was interested in your discussion about new drugs that are in development. as you're look at what the potential is, are you separating out fentanyl as a particular opioid that has very deadly properties and, therefore, requires a different kind of response, or are you lumping that in with everything else? >> we cannot lump it with everything else because what we are hearing from the field and being reported in -- [inaudible] is that when people overdose with fentanyl, the doses that we use of far can are not -- far can are not sufficient -- narcan. the other concern is you get exposed because of its potency, your risk of infection is much higher. as of now, we have not ever done a trial of how do you treat someo

dr. volkow and dr. koroshetz but also such hings as what to do about the neonatal abstinence syndrome which is of such deep donner all us. how best to manage what happens to those babies and what's their long term future? public-private partnership is actually a modest part of this broad portfolio but an important one. again, as we talked about earlier, the decision was made strong ased on recommendations that that should involve assets that are credited by industry that have value, data, compounds, scientific expertise but not a cash contribution. it is a little challenging right attach a dollar value to what their in kind contributions are going to add up to but it substantial. so putting that altogether, we think we're in a good place to public-private partnership and the rest of this broad portfolio together quite rapidly. >> good. you. dr. volkow, on the neonatal syndrome we have obviously, we're the state most highly affected by that as well, an area of deep concern to everybody. you see a lot, we

dr. volkow and dr. koroshetz but also such hings as what to do about the neonatal abstinence syndrome which is of such deep donner all us. how best to manage what happens to those babies and what's their long term future? public-private partnership is actually a modest part of this broad portfolio but an important one. again, as we talked about earlier, the decision was made strong ased on recommendations that that should involve assets that are credited by industry that have value, data, compounds, scientific expertise but not a cash contribution. it is a little challenging right attach a dollar value to what their in kind contributions are going to add up to but it substantial. so putting that altogether, we think we're in a good place to public-private partnership and the rest of this broad portfolio together quite rapidly. >> good. you. dr. volkow, on the neonatal syndrome we have obviously, we're the state most highly affected by that as well, an area of deep concern to everybody. you see a lot, we

dr. volkow very accurately characterizes the situation. i think one of the things that we are most concerned about in terms of this crisis, just if i can show you this graph, is the way in which the epidemic in terms of the overdose deaths has shifted from being prescription opioids to now fentanyl just going straight off the chart as it gets into the heroin supply, as more individuals who are fallen into addiction cannot find sufficient access to prescriptions then they shift over. >> absolutely. that's what we're seeing in new hampshire where we have the highest rate of overdose deaths from fentanyl. >> yes. >> dr. fauci, senator blunt mentioned the ebola epidemic and the news report this morning that said the first case had been found in an urban area, large city in the democratic republic of congo and given drc's other challenges how worried are we that that epidemic is going to get out of control again? >> well, obviously given our prior experience we are on very high alert. there are some factors that mitigate against their having th